NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading CCLD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making but has shown strong recent financial performance, making it a candidate for potential growth in the healthcare sector.
The market currently prices CCLD as expensive compared to its peers, with a premium of 0.34. There is an expectations gap indicating that the market has already factored in some level of performance improvement.
Management is on track to increase earnings per share significantly in 2026 and has reaffirmed revenue guidance. However, the trajectory towards these goals is mixed, and there is a notable risk of missing targets given the company's history.
The future performance of CCLD hinges on the guidance and earnings results from sector bellwethers like VEEV, BTSG, and TEM. If these companies continue to perform well, it could support CCLD's growth; conversely, any negative guidance from them could impact CCLD adversely.
In the next 1 to 3 years, CCLD's performance will depend heavily on sector dynamics and management's ability to meet its ambitious targets. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'favorable'.
No, our read on the company is unchanged. The management remains unsteady, which continues to be a concern, but recent financial performance is strong and holds in the top half of its industry. The supportive sector backdrop also helps maintain the current outlook.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Reaffirming EPS guidance shows confidence in profit growth. It impacts investor trust.
Confirms:Management confirms EPS guidance of $0.20–$0.23 for 2026 during the earnings call.
Disproves:Management cuts EPS guidance to below $0.20 during the earnings call.
Why it matters: Meeting or exceeding this growth rate shows CareCloud is on track with its revenue goals. It confirms the effectiveness of its AI expansion and capital structure changes.
Confirms:Q2 2026 revenue reported at or above $35.4 million, which is a 13% increase from Q1 2026.
Disproves:Q2 2026 revenue was below $35.4 million. This shows slower growth.
Why it matters: Reaffirming revenue guidance shows confidence in meeting growth targets. It impacts investor trust.
Confirms:Management reaffirms revenue guidance of $128M to $132M during the earnings call.
Disproves:Management lowered revenue guidance to below $128M. This may mean problems ahead.
Why it matters: Confirming adjusted EBITDA shows the company is doing well. It also helps investors feel secure.
Confirms:Management states adjusted EBITDA is on track for $29M to $31M during the earnings call.
Disproves:Adjusted EBITDA is below $29M. This means there are some operational problems.
Why it matters: Changes in leadership can affect strategy and performance. This may change investor confidence.
Confirms one read:Appointment of a new executive with a strong track record in healthcare.
Confirms the other:More key executives might leave. There are no clear replacements.
Why it matters: Meeting revenue guidance shows the company is on track for growth. It affects market perception.
Confirms:Q2 revenue reported between $31.27M and $33M, aligning with the $128M to $132M annual guidance.
Disproves:Q2 revenue falls below $31.27M, indicating struggles to meet annual targets.
Why it matters: Achieving this EPS growth shows strong profitability. It can improve market perception.
Confirms:EPS growth reported at 100% or more in Q3 2026.
Disproves:EPS growth reported below 100% in Q3 2026.
Why it matters: Changes in credit agreement terms may affect money use and growth plans.
Confirms one read:Positive updates on the credit agreement that improve terms or reduce costs.
Confirms the other:Negative updates on the credit agreement that increase costs or tighten terms.
Why it matters: The redemption may affect liquidity and investor confidence. It is a key financial event.
Confirms:The market reacted well. There was more money available after the redemption.
Disproves:The market reacted poorly. There were money problems after the redemption.
Why it matters: Hitting this target means CareCloud is making more money and controlling costs well. It shows their integration efforts are working.
Confirms:Adjusted EBITDA reported at $29 million or higher for the full year 2026.
Disproves:Adjusted EBITDA was below $29 million. This shows problems with managing costs.
Why it matters: Better GAAP net income shows stronger financial health and efficiency. It shows the effects of integration and cost control.
Confirms:GAAP net income reported above $922,000 for Q2 2026.
Disproves:GAAP net income reported below $922,000 for Q2 2026.
